

INTRODUCTION

Genetic obesity is rare, and quite challenging for pediatricians in terms of early identification. SH2B1 is an important component in the leptinmelanocortin pathway and is found to play an important role in leptin and insulin signaling, and therefore in the pathogenesis of obesity and diabetes. Microdeletions in chromosome 16p11.2, encompassing the SH2B1 gene, are known to be associated with obesity, insulin resistance, hyperphagia and developmental delay.

AIM

Aim of our study is to report on a case series of young individuals with 16p11.2 microdeletions, including the SH2B1 gene, and provide detailed information on BMI development and obesityassociated comorbidities.

In this way, we want to raise awareness of this syndromic form of obesity as a differential diagnosis of genetic obesity.

METHOD

inclusion criteria:

- obesity (> 97th percentile for age and sex*) and
- 16p11.2 deletions, including the SH2B1 gene, detected by MLPA
- Phenotype of 7 children (3 male; age range: 2.8 – 18.0 years)
- **BMI-trajectories from birth onwards**
- Screening for obesity-associated comorbidities

*according to German reference data by Kromeyer-Hauschild et al.

- Mb

Early genetic testing in suspicious patients and early screening for comorbidities is recommended.

Monogenic obesity in children: focusing on SH2B1 deletion

E. GIANNOPOULOU¹, S. ZORN¹, M. SCHIRMER¹, G. HERRMANN¹, S. HEGER², T. REINEHR³, C. DENZER¹, H. RABENSTEIN⁴, M. HILLMER⁴, N. SOWADA⁴, R. SIEBERT⁴, J. VON SCHNURBEIN¹ and M. WABITSCH¹ 1. Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany 2. Department of Pediatric Endocrinology, Children's Hospital Auf der Bult, Hannover, Germany 3. Department of Pediatric Endocrinology, Diabetes and Nutrition Medicine, Vestische Hospital for Children and Adolescents Datteln, University of Witten/Herdecke, Datteln, Germany


4. Institute of Human Genetics, Ulm University & Ulm University Medical Center, Ulm, Germany

RESULTS

Deletion size range: 0.060 – 1,710

 Inheritance: de novo in 4 patients, in the rest paternal/maternal

Phenotype: early onset obesity and variable, mild developmental delay (speech delay, motor delay, cognitive deficits, learning difficulties, ADHD, aggressive behavior)



CONCLUSIONS

Chromosomal microdeletions in 16p11.2, including the SH2B1 gene, in children are associated with severe, early-onset obesity and comorbidities associated with insulin resistance.

1 Ren D, Li M, Duan C, Rui L. Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice. Cell Metab. 2005 Aug;2(2):95-104

2 Rui L. SH2B1 regulation of energy balance, body weight, and glucose metabolism. World J Diabetes. 2014 Aug 15;5(4):511-26

3 Bachmann-Gagescu R et al. Recurrent 200-kb deletions of 16p11.2 that include the SH2B1 gene are associated with developmental delay and obesity. Genet Med. 2010 Oct;12(10):641-7

4 Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature. 2010 Feb 4;463(7281):666-70

5 Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiß HC, Hesse V, et al. Perzentile für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschrift Kinderheilkunde. 2001 2001/08/01;149(8):807-18.

Fig. 1. Individual BMI trajectories from birth of 7 children with microdeletions in chromosome 16p11.2, encompassing the SH2B1 gene.

Table 1. Laboratory findings in patients with microdeletions in chromosome 16p11.2, encompassing the SH2B1 gene.

Patient	Age (years)	Sex			Fasting insulin [mU/I]			Hepatic status*		Triglycerides [mg/dl]		LDL [mg/dl]
1	2.8	male	n/a	n/a	n/a	n/a	n/a	normal	153.0	291.0	n/a	n/a
2	18.5	female	64.8 (-2.5)	69.3	33.0	3.9	5.4	normal	143.1	96.3	46.4	96.7
3	7.7	female	64.6 (+1.1)	57.6	26.0	3.4	5.6	NAFLD	204.0	150.6	69.6	120.0
4	12.6	female	58.5 (-2.1)	51.4	78.0	6.2	8.4	NAFLD	143.0	114.0	43.0	97.0
5	16.8	female	62.9 (-2.6)	85.7	40.0	4.3	5.2	NAFLD	166.0	105.0	43.0	112.0
6	5.9	male	48.94 (-0.7)	42.17	39.9	4.0	5.5	NAFLD	154.7	132.9	46.4	92.8
7	5.0	male	11.0 (-0.5)	n/a	6.0	n/a	5.1	normal	168.0	56.0	56.0	101.0

*suspected NAFLD as assessed by liver enzymes and/or liver ultrasound

LEP: leptin, bioLEP: biologically active leptin, Hba1c: glycated haemoglobin A1c, NAFLD: non-alcoholic fatty liver disease, HDL: high-density lipoprotein, LDL: low-density lipoprotein, n/a: not available.

REFERENCES







ACKNOWLEDGEMENTS

We would like to thank all current and former members of molecular genetics laboratory of the Institute of Human Genetics. In addition, we thank all children and their families for their participation.

CONTACT INFORMATION

Dr. E. Giannopoulou

Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, Ulm University, Eythstr. 24, 89075, Ulm, Germany

Email: Eleni.Giannopoulou@uniklinik-ulm.de

